SQI has made steady progress over recent months in signing new agreements with drug development companies in its high-volume assay business. Encouragingly, service revenues are now booked for custom-made tests early on in development, albeit at modest levels. While the conversion of customers from early contract work/validation to meaningful revenue-generating accounts is slower than expected, industry interest continues to grow steadily for SQI’s multiplexing technology capabilities, a
29 Sep 2015
Tapping into considerable market opportunities
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Tapping into considerable market opportunities
SQI has made steady progress over recent months in signing new agreements with drug development companies in its high-volume assay business. Encouragingly, service revenues are now booked for custom-made tests early on in development, albeit at modest levels. While the conversion of customers from early contract work/validation to meaningful revenue-generating accounts is slower than expected, industry interest continues to grow steadily for SQI’s multiplexing technology capabilities, a